Trio Medicines
UK - LondonBiotechnology
Focus: Trio Medicines is a UK-based biotech founded in 2007 focused on small molecules and biologics across oncology and gastrointestinal indications. The company operates at early-stage development with a pipeline concentrated in Phase 1–2 programs.
Profile data last refreshed 10h ago · AI intelligence enriched 1w ago
Open Jobs
1
Should You Work at Trio Medicines?
AI assessmentTrio represents a high-risk, high-learning opportunity suitable for scientists seeking early-stage drug discovery work, but unsuitable for those prioritizing job security, rapid advancement, or near-term commercial impact.
Why Work Here
- Early-stage biotech environment offers hands-on ownership of drug discovery and development projects with direct impact on program outcomes.
Data completeness
2/9 — Limited
Company HealthSolid
Pipeline
Early-stage
15 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
YF476
HypergastrinaemiaClinical Trials (1)
NCT01699113Effects of YF476 and Rabeprazole on Gastric Function
Phase 1Help build intelligence for Trio Medicines
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.